特发性颅内压增高治疗试验6个月生活质量分析
本研究基于特发性颅内压增高治疗试验(IIHTT),评估165例轻度视力下降的IIH患者6个月时视功能特异性与总体健康相关生活质量变化。结果显示乙酰唑胺在所有生活质量量表上均有获益,其效应主要由视野、颈痛、搏动性耳鸣和头晕/眩晕的改善介导,且超过药物副作用。
要点
- 乙酰唑胺改善IIH患者6个月时多项生活质量量表评分。
- 生活质量获益主要由视野、颈痛、搏动性耳鸣及头晕/眩晕改善介导。
- 结果支持乙酰唑胺联合饮食干预治疗轻度视力下降的IIH。
核心结论
- 对轻度视力下降的IIH患者,乙酰唑胺治疗可改善其显著降低的基线生活质量。
- 乙酰唑胺对生活质量的正面影响主要由视野、颈痛、搏动性耳鸣和头晕/眩晕的改善介导,并超过其副作用。
研究设计与样本
- 研究为IIHTT的一部分,纳入165例伴轻度视力下降的IIH患者,其中86例随机接受乙酰唑胺、79例接受安慰剂。
- 使用NEI-VFQ-25、10项NEI-VFQ-25神经眼科补充问卷和SF-36评估生活质量,采用线性模型和结构方程模型分析6个月内变化。
主要发现
- 乙酰唑胺在所有评估的生活质量量表上均显示有益效应。
- NEI-VFQ-25近活动亚量表改善5.60分(p = 0.03)。
- NEI-VFQ-25社会功能亚量表改善3.85分(p = 0.04)。
- NEI-VFQ-25心理健康亚量表改善9.82分(p = 0.04)。
临床怎么用
- 对轻度视力下降的IIH患者,可在饮食干预基础上加用乙酰唑胺以改善生活质量。
- 临床关注视野、颈痛、搏动性耳鸣和头晕/眩晕的改善,这些变化与生活质量获益相关。
局限性
- 摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the changes in vision-specific and overall health-related quality of life (QOL) at 6 months in participants with idiopathic intracranial hypertension (IIH) and mild visual loss enrolled in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) and to determine the signs and symptoms of IIH that mediate the effect of acetazolamide on QOL. METHODS: We assessed QOL using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25), the 10-Item NEI-VFQ-25 Neuro-Ophthalmic Supplement, and the 36-Item Short Form Health Survey (SF-36). We examined associations among changes in QOL measures over 6 months, treatment status, and changes in signs and symptoms using linear and structural equation models. RESULTS: Among the 165 participants with IIH (86 randomized to acetazolamide, 79 to placebo), beneficial effects of acetazolamide were seen on all QOL scales evaluated, as well as on the Near Activities (5.60 points, p = 0.03), Social Functioning (3.85 points, p = 0.04), and Mental Health (9.82, p = 0.04) subscales of the NEI-VFQ-25. Positive acetazolamide-related effects on QOL appeared to be primarily mediated by improvements in visual field, neck pain, pulsatile tinnitus, and dizziness/vertigo that outweighed the side effects of acetazolamide. CONCLUSIONS: The marked reductions in baseline QOL seen among patients with mild visual loss from IIH are improved by treatment with acetazolamide. When combined with acetazolamide-associated improvements in visual field and other aspects of IIH, our findings with respect to QOL provide further support from the IIHTT in favor of acetazolamide to augment a dietary intervention in the treatment of IIH with mild visual loss (clinicaltrials.gov: NCT01003639).
引用
- Bruce BB, Digre KB, McDermott MP, et al. Quality of life at 6 months in the Idiopathic Intracranial Hypertension Treatment Trial. Neurology. 2016. PMID: 27694262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。